Gland Pharma board meet Jan 28, 2026: Q3 results

What the board meeting update said

Gland Pharma informed the stock exchanges that its Board of Directors would meet on Wednesday, January 28, 2026. The stated purpose was to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The intimation was published with a timestamp of January 9, 2026 (12:24 pm) and cited BSE as the source. The company also shared compliance-related details around the trading window closure and reopening. Alongside the results agenda, the communication referenced an Investor/Analyst call scheduled for the same day. These updates matter for investors because they set expectations on when financial numbers will be released and when management commentary may be available.

Key dates and timings investors tracked

The exchange filing placed three dates at the center of the update: the board meeting date, the trading window reopening date, and the analyst call time. The trading window was stated to have been closed from December 27, 2025. It was slated to reopen on Saturday, January 31, 2026. The Investor/Analyst call was scheduled for January 28, 2026 at 18:30 hrs (IST). The company said further call details would be shared with stock exchanges and hosted on its website.

What the board approved after the meeting

In a subsequent update referencing the earlier January 9 intimation, the company said the Board met on Wednesday, January 28, 2026. It stated the Board considered and approved unaudited financial results (standalone and consolidated) along with limited review report(s). The company also disclosed the meeting timings, stating it commenced at 15:00 hrs IST and concluded at 16:15 hrs IST. This disclosure helps the market confirm the results approval process was completed on the scheduled day.

Results context: quarter and nine months ended Dec 31, 2025

The agenda described the reporting period clearly. The Board’s review covered the quarter ended December 31, 2025, and the nine-month period ended December 31, 2025. The company positioned these as unaudited results for both standalone and consolidated financials. A company release dated January 28, 2026 also described the announcement as financial results for the third quarter ended December 31, 2025. The stock exchange communication and the company update were aligned on the reporting cut-off date.

Company release highlights mentioned with Q3 FY26

Gland Pharma described its third-quarter performance with two headline growth metrics. It stated revenue grew 22% year-on-year. It also stated adjusted PAT grew 37%. These figures were presented as part of the company’s results communication dated January 28, 2026. The release identified Gland Pharma as a generic injectable-focused pharmaceutical company and referenced its exchange identifiers (BSE: 543245 | NSE: GLAND). Beyond these headline growth rates, the provided text did not include absolute revenue or profit numbers for the quarter.

Governance item: internal auditor reappointment

Apart from the financial results, the Board also took up an appointment-related item. The company stated it approved the reappointment of M/s Grant Thornton Bharat LLP as Internal Auditors. The reappointment was specified for the financial year 2026-27. Such disclosures are typically tracked by investors as they reflect governance processes and continuity in internal controls oversight. The update did not provide additional terms of appointment in the provided text.

Trading window closure and reopening

The company reiterated that the trading window had been closed from Saturday, December 27, 2025. It also confirmed the trading window would reopen for trading activities on Saturday, January 31, 2026. These dates are relevant under insider trading regulations, especially for designated persons and connected individuals. The closure and reopening frame the period during which trading restrictions were in place around the results cycle.

How this fits into Gland Pharma’s board meeting calendar

The provided schedule lists multiple board meeting dates tied to results. It includes August 5, 2025 (quarterly results), November 3, 2025 (quarterly results), January 28, 2026 (quarterly results), and May 15, 2026 (audited results and final dividend). A separate historical table also lists May 20, 2025 (audited results and final dividend), February 3, 2025 (quarterly results), November 4, 2024 (quarterly results), and August 6, 2024 (quarterly results). Together, these entries show a pattern of results-linked board meetings through the year.

Prior market narrative referenced in the provided text

The dataset also included a separate market note stating Gland Pharma shares surged after strong Q1 results and broker commentary pointing to a turnaround at its European unit Cenexi. That note cited EBITDA margins expanding to 24.4% and net profit rising 50% year-on-year. It also said that while U.S. sales were weak, growth in Europe and new launches supported the outlook. This context was included alongside board-meeting related items, but it is distinct from the January 28, 2026 board meeting intimation and approval update.

Key facts table

Board meeting dates listed in the provided schedule

What to watch next

The company said additional details for the Investor/Analyst call would be shared through stock exchanges and on its website. Investors typically use such calls to understand management commentary around the quarter and nine-month performance referenced in the filing. Separately, the provided dataset included projected earnings release dates, but these were explicitly labelled as projected and not presented as company-confirmed schedules in the exchange communication. For the January results cycle specifically, the confirmed milestones in the text were the board meeting on January 28, 2026 and the trading window reopening on January 31, 2026.

Conclusion

Gland Pharma’s January 28, 2026 board meeting was convened to approve unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, and the company later confirmed the approvals along with the meeting timings. The disclosure also set out the trading window reopening date and the timing of the Investor/Analyst call. In addition, the Board reappointed Grant Thornton Bharat LLP as internal auditors for FY 2026-27. The next confirmed step mentioned in the text is the dissemination of further details for the scheduled analyst call through stock exchanges and the company website.